These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long term evaluation of etiological treatment of chagas disease with benznidazole. Cancado JR Rev Inst Med Trop Sao Paulo; 2002; 44(1):29-37. PubMed ID: 11896410 [TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Marin-Neto JA; Rassi A; Morillo CA; Avezum A; Connolly SJ; Sosa-Estani S; Rosas F; Yusuf S; Am Heart J; 2008 Jul; 156(1):37-43. PubMed ID: 18585495 [TBL] [Abstract][Full Text] [Related]
7. Heart rate variability in chronic Chagas patients before and after treatment with benznidazole. Oliveira LF; Silva VJ; Lages-Silva E; Molina RJ; Fuzissaki J; Niederhaur S; Prata A; Correia D Auton Neurosci; 2010 Dec; 158(1-2):118-22. PubMed ID: 20558113 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550 [TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534 [TBL] [Abstract][Full Text] [Related]
11. [Longitudinal study of the persistence of the therapeutic action of nifurtimox and benznidazole in patients with chronic chagas infection]. Schenone H; Rojas A; Alfaro E; Concha L; Aranda R Bol Chil Parasitol; 1981; 36(3-4):59-62. PubMed ID: 6812600 [No Abstract] [Full Text] [Related]
12. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy. Bustamante JM; Presti MS; Rivarola HW; Fernández AR; Enders JE; Fretes RE; Paglini-Oliva P Int J Antimicrob Agents; 2007 Jun; 29(6):733-7. PubMed ID: 17395432 [TBL] [Abstract][Full Text] [Related]
13. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. Nogueira Silva JJ; Pavanelli WR; Gutierrez FR; Alves Lima FC; Ferreira da Silva AB; Santana Silva J; Wagner Franco D J Med Chem; 2008 Jul; 51(14):4104-14. PubMed ID: 18570370 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials. Molina I; Salvador F; Sánchez-Montalvá A; Artaza MA; Moreno R; Perin L; Esquisabel A; Pinto L; Pedraz JL Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167552 [TBL] [Abstract][Full Text] [Related]
15. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164 [TBL] [Abstract][Full Text] [Related]
16. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study. Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082 [TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Shiah HS; Chao Y; Chen LT; Yao TJ; Huang JD; Chang JY; Chen PJ; Chuang TR; Chin YH; Whang-Peng J; Liu TW Cancer Chemother Pharmacol; 2006 Nov; 58(5):654-64. PubMed ID: 16520988 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina]. Sosa Estani S; Segura EL Medicina (B Aires); 1999; 59 Suppl 2():166-70. PubMed ID: 10668259 [TBL] [Abstract][Full Text] [Related]
19. [Use of thioctic acid for prevention of the adverse effects induced by benznidazole in patients with chronic Chagas' infection]. Carpintero DJ Medicina (B Aires); 1983; 43(3):285-90. PubMed ID: 6423926 [No Abstract] [Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Smith RB; Gwilt PR; Wright CE Clin Pharm; 1983; 2(2):139-43. PubMed ID: 6883942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]